{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:06:36Z","timestamp":1771027596734,"version":"3.50.1"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671448"],"award-info":[{"award-number":["81671448"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7162152"],"award-info":[{"award-number":["7162152"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s10557-019-06851-7","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T14:30:42Z","timestamp":1548340242000},"page":"119-128","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Two Birds with One Stone: Regular Use of PDE5 Inhibitors for Treating Male Patients with Erectile Dysfunction and Cardiovascular Diseases"],"prefix":"10.1007","volume":"33","author":[{"given":"Zhonglin","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"issue":"1","key":"6851_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/imj.12325","volume":"44","author":"CG McMahon","year":"2014","unstructured":"McMahon CG. Erectile dysfunction. Intern Med J. 2014;44(1):18\u201326.","journal-title":"Intern Med J"},{"issue":"10","key":"6851_CR2","first-page":"820","volume":"94","author":"KT Rew","year":"2016","unstructured":"Rew KT, Heidelbaugh JJ. Erectile dysfunction. Am Fam Physician. 2016;94(10):820\u20137.","journal-title":"Am Fam Physician"},{"issue":"2","key":"6851_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.2174\/1570161115666170609101502","volume":"16","author":"KP Imprialos","year":"2018","unstructured":"Imprialos KP, Stavropoulos K, Doumas M, et al. Sexual dysfunction, cardiovascular risk and effects of pharmacotherapy. Curr Vasc Pharmacol. 2018;16(2):130\u201342.","journal-title":"Curr Vasc Pharmacol"},{"issue":"1","key":"6851_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/CIRCOUTCOMES.112.966903","volume":"6","author":"CV Vlachopoulos","year":"2013","unstructured":"Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013;6(1):99\u2013109.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"6851_CR5","unstructured":"Uddin SMI, Mirbolouk M, Dardari Z, et al. Erectile dysfunction as an independent predictor of future cardiovascular events: the multi-ethnic study of atherosclerosis. Circulation. 2018, pii: CIRCULATIONAHA.118.033990."},{"issue":"2","key":"6851_CR6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/13685538.2015.1129400","volume":"19","author":"CH Ho","year":"2016","unstructured":"Ho CH, Wu CC, Chen KC, et al. Erectile dysfunction, loss of libido and low sexual frequency increase the risk of cardiovascular disease in men with low testosterone. Aging Male. 2016;19(2):96\u2013101.","journal-title":"Aging Male"},{"issue":"10","key":"6851_CR7","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.2337\/dc13-0294","volume":"36","author":"SJ Turek","year":"2013","unstructured":"Turek SJ, Hastings SM, Sun JK, et al. Sexual dysfunction as a marker of cardiovascular disease in males with 50 or more years of type 1 diabetes. Diabetes Care. 2013;36(10):3222\u20136.","journal-title":"Diabetes Care"},{"issue":"1","key":"6851_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12872-017-0576-4","volume":"17","author":"IC Hwang","year":"2017","unstructured":"Hwang IC, Kim YJ, Park JB, et al. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials. BMC Cardiovasc Disord. 2017;17(1):150.","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"6851_CR9","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ejhf.711","volume":"19","author":"C M\u00e1ty\u00e1s","year":"2017","unstructured":"M\u00e1ty\u00e1s C, N\u00e9meth BT, Ol\u00e1h A, et al. Prevention of the development of heart failure with preserved ejection fraction by the phosphodiesterase-5A inhibitor vardenafil in rats with type 2 diabetes. Eur J Heart Fail. 2017;19(3):326\u201336.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"6851_CR10","doi-asserted-by":"publisher","first-page":"e0195528","DOI":"10.1371\/journal.pone.0195528","volume":"13","author":"Y Imai","year":"2018","unstructured":"Imai Y, Kariya T, Iwakiri M, et al. Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload. PLoS One. 2018;13(4):e0195528.","journal-title":"PLoS One"},{"issue":"10","key":"6851_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/1440-1681.12290","volume":"41","author":"KH Lee","year":"2014","unstructured":"Lee KH, Kwon SJ, Woo JS, et al. Effects of sildenafil on nanostructural and nanomechanical changes in mitochondria in an ischaemia-reperfusion rat model. Clin Exp Pharmacol Physiol. 2014;41(10):763\u20138.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"24","key":"6851_CR12","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1161\/CIRCULATIONAHA.117.028723","volume":"136","author":"S Frankenreiter","year":"2017","unstructured":"Frankenreiter S, Bednarczyk P, Kniess A, et al. cGMP-elevating compounds and ischemic conditioning provide cardioprotection against ischemia and reperfusion injury via cardiomyocyte-specific BK channels. Circulation. 2017;136(24):2337\u201355.","journal-title":"Circulation"},{"issue":"1","key":"6851_CR13","doi-asserted-by":"publisher","first-page":"e1001372","DOI":"10.1371\/journal.pmed.1001372","volume":"10","author":"E Banks","year":"2013","unstructured":"Banks E, Joshy G, Abhayaratna WP, et al. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality: a prospective cohort study. PLoS Med. 2013;10(1):e1001372.","journal-title":"PLoS Med"},{"key":"6851_CR14","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357:j2099.","journal-title":"BMJ"},{"issue":"3","key":"6851_CR15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.amjmed.2013.10.013","volume":"127","author":"M Miner","year":"2014","unstructured":"Miner M, Nehra A, Jackson G, et al. All men with vasculogenic erectile dysfunction require a cardiovascular workup. Am J Med. 2014;127(3):174\u201382.","journal-title":"Am J Med"},{"issue":"1","key":"6851_CR16","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/sj.ijir.3901604","volume":"20","author":"BW Schouten","year":"2008","unstructured":"Schouten BW, Bohnen AM, Bosch JL, et al. Erectile dysfunction prospectively associated with cardiovascular disease in the Dutch general population: results from the Krimpen Study. Int J Impot Res. 2008;20(1):92\u20139.","journal-title":"Int J Impot Res"},{"issue":"5","key":"6851_CR17","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/2047487316686434","volume":"24","author":"L Compostella","year":"2017","unstructured":"Compostella L, Compostella C, Truong LV, et al. History of erectile dysfunction as a predictor of poor physical performance after an acute myocardial infarction. Eur J Prev Cardiol. 2017;24(5):460\u20137.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"6851_CR18","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.amjcard.2009.08.671","volume":"105","author":"SA Hall","year":"2010","unstructured":"Hall SA, Shackelton R, Rosen RC, et al. Sexual activity, erectile dysfunction, and incident cardiovascular events. Am J Cardiol. 2010;105(2):192\u20137.","journal-title":"Am J Cardiol"},{"issue":"16","key":"6851_CR19","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/heartjnl-2016-310746","volume":"103","author":"DP Andersson","year":"2017","unstructured":"Andersson DP, Trolle Lagerros Y, Grotta A, et al. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017;103(16):1264\u201370.","journal-title":"Heart"},{"key":"6851_CR20","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ijcard.2017.05.079","volume":"243","author":"D Tobler","year":"2017","unstructured":"Tobler D, Bouchardy J, Reto E, et al. Effect of phosphodiesterase-5 inhibition with tadalafil on systemic right ventricular size and function\u2014a multi-center, double-blind, randomized, placebo-controlled clinical trial\u2014serve trial\u2014rational and design. Int J Cardiol. 2017;243:354\u20139.","journal-title":"Int J Cardiol"},{"issue":"6","key":"6851_CR21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s00395-012-0308-y","volume":"107","author":"D Westermann","year":"2012","unstructured":"Westermann D, Becher PM, Lindner D, et al. Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol. 2012;107(6):308.","journal-title":"Basic Res Cardiol"},{"key":"6851_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1479-5876-10-159","volume":"10","author":"JS Wang","year":"2012","unstructured":"Wang JS, Kovanecz I, Vernet D, et al. Effects of sildenafil and\/or muscle derived stem cells on myocardial infarction. J Transl Med. 2012;10:159.","journal-title":"J Transl Med"},{"issue":"1\u20133","key":"6851_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejphar.2012.05.015","volume":"690","author":"TM Lee","year":"2012","unstructured":"Lee TM, Chen CC, Chung TH, et al. Effect of sildenafil on ventricular arrhythmias in post-infarcted rat hearts. Eur J Pharmacol. 2012;690(1\u20133):124\u201332.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"6851_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/14017431.2012.732235","volume":"47","author":"AA Mennander","year":"2013","unstructured":"Mennander AA, Vuohelainen V, Aanismaa RS, et al. Sildenafil after cardiac arrest and infarction; an experimental rat model. Scand Cardiovasc J Suppl. 2013;47(1):58\u201364.","journal-title":"Scand Cardiovasc J Suppl"},{"issue":"21","key":"6851_CR25","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/heartjnl-2015-309223","volume":"102","author":"SG Anderson","year":"2016","unstructured":"Anderson SG, Hutchings DC, Woodward M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016;102(21):1750\u20136.","journal-title":"Heart"},{"issue":"3","key":"6851_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4239\/wjd.v8.i3.104","volume":"8","author":"G Hackett","year":"2017","unstructured":"Hackett G, Jones PW, Strange RC, et al. Statin, testosterone and phosphodiesterase 5-inhibitor treatments and age related mortality in diabetes. World J Diabetes. 2017;8(3):104\u201311.","journal-title":"World J Diabetes"},{"issue":"3","key":"6851_CR27","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/ijcp.12779","volume":"70","author":"G Hackett","year":"2016","unstructured":"Hackett G, Heald AH, Sinclair A, et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Prxzact. 2016;70(3):244\u201353.","journal-title":"Int J Clin Prxzact"},{"issue":"5A","key":"6851_CR28","doi-asserted-by":"publisher","first-page":"3C","DOI":"10.1016\/S0002-9149(99)00042-9","volume":"83","author":"RM Wallis","year":"1999","unstructured":"Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999;83(5A):3C\u201312C.","journal-title":"Am J Cardiol"},{"issue":"6","key":"6851_CR29","doi-asserted-by":"publisher","first-page":"H2272","DOI":"10.1152\/ajpheart.00654.2010","volume":"300","author":"VQ Chau","year":"2011","unstructured":"Chau VQ, Salloum FN, Hoke NN, et al. Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA\/Rho-kinase pathway. Am J Physiol Heart Circ Physiol. 2011;300(6):H2272\u20139.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"6851_CR30","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1177\/0003319710362977","volume":"61","author":"E Bon De","year":"2010","unstructured":"De Bon E, Bonanni G, Saggiorato G, et al. Effects of tadalafil on platelets and endothelium in patients with erectile dysfunction and cardiovascular risk factors: a pilot study. Angiology. 2010;61(6):602\u20136.","journal-title":"Angiology"},{"issue":"7","key":"6851_CR31","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/S0735-1097(02)02139-3","volume":"40","author":"JP Halcox","year":"2002","unstructured":"Halcox JP, Nour KR, Zalos G, et al. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol. 2002;40(7):1232\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"6851_CR32","doi-asserted-by":"crossref","unstructured":"Hutchings DC, Anderson SG, Caldwell JL, et al. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018. pii: heartjnl-2017-312865.","DOI":"10.1136\/heartjnl-2017-312865"},{"issue":"36","key":"6851_CR33","doi-asserted-by":"publisher","first-page":"13650","DOI":"10.1073\/pnas.0804738105","volume":"105","author":"LS Wilson","year":"2008","unstructured":"Wilson LS, Elbatarny HS, Crawley SW, et al. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMP-mediated regulation of platelet functions. Proc Natl Acad Sci U S A. 2008;105(36):13650\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6851_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.niox.2018.03.008","volume":"76","author":"S Makhoul","year":"2018","unstructured":"Makhoul S, Walter E, Pagel O, et al. Effects of the NO\/soluble guanylate cyclase\/cGMP system on the functions of human platelets. Nitric Oxide. 2018;76:71\u201380.","journal-title":"Nitric Oxide"},{"issue":"1","key":"6851_CR35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1006\/bbrc.2001.5547","volume":"287","author":"SL Bodie","year":"2001","unstructured":"Bodie SL, Ford I, Greaves M, et al. Thrombin-induced activation of RhoA in platelet shape change. Biochem Biophys Res Commun. 2001;287(1):71\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"6851_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1055\/s-0037-1613448","volume":"89","author":"D Libersan","year":"2003","unstructured":"Libersan D, Rousseau G, Merhi Y. Differential regulation of P-selectin expression by protein kinase A and protein kinase G in thrombin-stimulated human platelets. Thromb Haemost. 2003;89(2):310\u20137.","journal-title":"Thromb Haemost"},{"issue":"9","key":"6851_CR37","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/blood-2004-03-1058","volume":"104","author":"BO Jensen","year":"2004","unstructured":"Jensen BO, Selheim F, D\u00f8skeland SO, et al. Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood. 2004;104(9):2775\u201382.","journal-title":"Blood"},{"issue":"9","key":"6851_CR38","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham YK, Bernardo BC, Ooi JY, et al. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol. 2015;89(9):1401\u201338.","journal-title":"Arch Toxicol"},{"issue":"4","key":"6851_CR39","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.yjmcc.2009.11.015","volume":"48","author":"N Koitabashi","year":"2010","unstructured":"Koitabashi N, Aiba T, Hesketh GG, et al. Cyclic GMP\/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol. 2010;48(4):713\u201324.","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"6851_CR40","first-page":"408","volume":"119","author":"E Takimoto","year":"2009","unstructured":"Takimoto E, Koitabashi N, Hsu S, et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest. 2009;119(2):408\u201320.","journal-title":"J Clin Invest"},{"issue":"9","key":"6851_CR41","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1161\/01.ATV.0000176193.83629.c8","volume":"25","author":"H Shimokawa","year":"2005","unstructured":"Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol. 2005;25(9):1767\u201375.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"6851_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10557-014-6559-0","volume":"28","author":"FN Salloum","year":"2014","unstructured":"Salloum FN, Chau VQ, Hoke NN, et al. Tadalafil prevents acute heart failure with reduced ejection fraction in mice. Cardiovasc Drugs Ther. 2014;28(6):493\u2013500.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6851_CR43","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.2741\/4450","volume":"21","author":"N Li","year":"2016","unstructured":"Li N, Yuan Y, Li S, et al. PDE5 inhibitors protect against post-infarction heart failure. Front Biosci (Landmark Ed). 2016;21:1194\u2013210.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"7","key":"6851_CR44","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/bph.12346","volume":"170","author":"W Gong","year":"2013","unstructured":"Gong W, Duan Q, Cai Z, et al. Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. Br J Pharmacol. 2013;170(7):1396\u2013409.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"6851_CR45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s40618-015-0340-5","volume":"39","author":"C Corinaldesi","year":"2016","unstructured":"Corinaldesi C, Di Luigi L, Lenzi A, et al. Phosphodiesterase type 5 inhibitors: back and forward from cardiac indications. J Endocrinol Investig. 2016;39(2):143\u201351.","journal-title":"J Endocrinol Investig"},{"issue":"4","key":"6851_CR46","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11684-014-0378-3","volume":"8","author":"W Gong","year":"2014","unstructured":"Gong W, Yan M, Chen J, et al. Chronic inhibition of cyclic guanosine monophosphate-specific phosphodiesterase 5 prevented cardiac fibrosis through inhibition of transforming growth factor \u03b2-induced Smad signaling. Front Med. 2014;8(4):445\u201355.","journal-title":"Front Med"},{"issue":"22","key":"6851_CR47","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1016\/j.jacc.2011.09.086","volume":"59","author":"RC Kukreja","year":"2012","unstructured":"Kukreja RC, Salloum FN, Das A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J Am Coll Cardiol. 2012;59(22):1921\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6851_CR48","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/cvr\/cvy039","volume":"114","author":"S Frankenreiter","year":"2018","unstructured":"Frankenreiter S, Groneberg D, Kuret A, et al. Cardioprotection by ischemic postconditioning and cyclic guanosine monophosphate-elevating agents involves cardiomyocyte nitric oxide-sensitive guanylyl cyclase. Cardiovasc Res. 2018;114(6):822\u20139.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"6851_CR49","doi-asserted-by":"publisher","first-page":"e0144737","DOI":"10.1371\/journal.pone.0144737","volume":"10","author":"F Behmenburg","year":"2015","unstructured":"Behmenburg F, Dorsch M, Huhn R, et al. Impact of mitochondrial Ca2+-sensitive potassium (mBKCa) channels in sildenafil-induced cardioprotection in rats. PLoS One. 2015;10(12):e0144737.","journal-title":"PLoS One"},{"issue":"3","key":"6851_CR50","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1124\/pr.110.002907","volume":"62","author":"SH Francis","year":"2010","unstructured":"Francis SH, Busch JL. Corbin JD, et al. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev. 2010;62(3):525\u201363.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"6851_CR51","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/FJC.0000000000000330","volume":"67","author":"Y Gao","year":"2016","unstructured":"Gao Y. Conventional and unconventional mechanisms for soluble guanylyl cyclase signaling. J Cardiovasc Pharmacol. 2016;67(5):367\u201372.","journal-title":"J Cardiovasc Pharmacol"},{"key":"6851_CR52","first-page":"360","volume":"j5492","author":"T Thenappan","year":"2018","unstructured":"Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;j5492:360.","journal-title":"BMJ"},{"key":"6851_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejphar.2017.06.010","volume":"810","author":"A Yamamura","year":"2017","unstructured":"Yamamura A, Fujitomi E, Ohara N, et al. Tadalafil induces antiproliferation, apoptosis, and phosphodiesterase type 5 downregulation in idiopathic pulmonary arterial hypertension in vitro. Eur J Pharmacol. 2017;810:44\u201350.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"6851_CR54","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1213\/01.ane.0000278736.81133.26","volume":"105","author":"B Li","year":"2007","unstructured":"Li B, Yang L, Shen J, et al. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1\/2 phosphorylation. Anesth Analg. 2007;105(4):1034\u201341 table of contents.","journal-title":"Anesth Analg"},{"issue":"2","key":"6851_CR55","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1165\/rcmb.2012-0185OC","volume":"49","author":"J Wang","year":"2013","unstructured":"Wang J, Yang K, Xu L, et al. Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPAR\u03b3 axis. Am J Respir Cell Mol Biol. 2013;49(2):231\u201340.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"6851_CR56","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1254\/jphs.08069FP","volume":"108","author":"C Wang","year":"2008","unstructured":"Wang C, Wang J, Zhao L, et al. Sildenafil inhibits human pulmonary artery smooth muscle cell proliferation by decreasing capacitative Ca2+ entry. J Pharmacol Sci. 2008;108(1):71\u20138.","journal-title":"J Pharmacol Sci"},{"issue":"1 Suppl","key":"6851_CR57","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jacc.2009.04.018","volume":"54","author":"NW Morrell","year":"2009","unstructured":"Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S20\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"6851_CR58","first-page":"159","volume":"4","author":"SL Washington 3rd","year":"2010","unstructured":"Washington SL 3rd, Shindel AW. A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. Drug Des Devel Ther. 2010;4:159\u201371.","journal-title":"Drug Des Devel Ther"},{"issue":"8","key":"6851_CR59","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1093\/ajh\/hpx060","volume":"30","author":"AD Lane-Cordova","year":"2017","unstructured":"Lane-Cordova AD, Kershaw K, Liu K, et al. Association between cardiovascular health and endothelial function with future erectile dysfunction: the multi-ethnic study of atherosclerosis. Am J Hypertens. 2017;30(8):815\u201321.","journal-title":"Am J Hypertens"},{"issue":"3","key":"6851_CR60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/ijir.2016.47","volume":"29","author":"O \u00d6zdabako\u011flu","year":"2017","unstructured":"\u00d6zdabako\u011flu O, G\u00fcll\u00fcl\u00fc S, Sa\u011f S, et al. Evaluation of arterial stiffness and cardiac function in patients with vascular erectile dysfunction: acute effects of phosphodiesterase-5 inhibitor tadalafil. Int J Impot Res. 2017;29(3):96\u2013100.","journal-title":"Int J Impot Res"},{"issue":"7","key":"6851_CR61","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/dmrr.1223","volume":"27","author":"P Kempler","year":"2011","unstructured":"Kempler P, Amarenco G, Freeman R, et al. Management strategies for gastrointestinal, erectile, bladder, and sudomotor dysfunction in patients with diabetes. Diabetes Metab Res Rev. 2011;27(7):665\u201377.","journal-title":"Diabetes Metab Res Rev"},{"key":"6851_CR62","doi-asserted-by":"publisher","first-page":"32853","DOI":"10.1038\/srep32853","volume":"6","author":"S Qiu","year":"2016","unstructured":"Qiu S, Tang Z, Deng L, et al. Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer. Sci Rep. 2016;6:32853.","journal-title":"Sci Rep"},{"issue":"4","key":"6851_CR63","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.urology.2012.06.042","volume":"80","author":"V Javaroni","year":"2012","unstructured":"Javaroni V, Queiroz Miguez M, Burla A, et al. Response to on-demand vardenafil was improved by its daily usage in hypertensive men. Urology. 2012;80(4):858\u201364.","journal-title":"Urology"},{"issue":"2","key":"6851_CR64","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1185\/03007995.2014.989317","volume":"31","author":"E Kim","year":"2015","unstructured":"Kim E, Seftel A, Goldfischer E, et al. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil. Curr Med Res Opin. 2015;31(2):379\u201389.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"6851_CR65","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jsxm.2016.01.023","volume":"13","author":"G Hackett","year":"2016","unstructured":"Hackett G, Krychman M, Baldwin D, et al. Coronary heart disease, diabetes, and sexuality in men. J Sex Med. 2016;13(6):887\u2013904.","journal-title":"J Sex Med"},{"key":"6851_CR66","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.atherosclerosis.2016.06.018","volume":"251","author":"MT Kratz","year":"2016","unstructured":"Kratz MT, Schirmer SH, Baumh\u00e4kel M, et al. Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism. Atherosclerosis. 2016;251:291\u20138.","journal-title":"Atherosclerosis"},{"issue":"2","key":"6851_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2174\/1570161114666151202205617","volume":"14","author":"J Pernow","year":"2016","unstructured":"Pernow J, Jung C. The emerging role of arginase in endothelial dysfunction in diabetes. Curr Vasc Pharmacol. 2016;14(2):155\u201362.","journal-title":"Curr Vasc Pharmacol"},{"issue":"11","key":"6851_CR68","first-page":"1195","volume":"62","author":"H Jamshidian","year":"2012","unstructured":"Jamshidian H, Borhan A, Kooraki S, et al. Evaluation of the efficacy of once-daily use of tadalafil vs. on-demand use. Is there a cumulative effect? J Pak Med Assoc. 2012;62(11):1195\u20138.","journal-title":"J Pak Med Assoc"},{"issue":"1","key":"6851_CR69","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1754-9485.2012.02461.x","volume":"57","author":"D Ilic","year":"2013","unstructured":"Ilic D, Hindson B, Duchesne G, et al. A randomised, double-blind, placebo-controlled trial of nightly sildenafil citrate to preserve erectile function after radiation treatment for prostate cancer. J Med Imaging Radiat Oncol. 2013;57(1):81\u20138.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"1","key":"6851_CR70","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ijir.2014.19","volume":"27","author":"H Choi","year":"2015","unstructured":"Choi H, Kim JH, Shim JS, et al. Comparison of the efficacy and safety of 5-mg once-daily versus 5-mg alternate-day tadalafil in men with erectile dysfunction and lower urinary tract symptoms. Int J Impot Res. 2015;27(1):33\u20137.","journal-title":"Int J Impot Res"},{"key":"6851_CR71","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1001\/archinte.166.2.231","volume":"166","author":"E Caglayan","year":"2006","unstructured":"Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterasetype 5 inhibition is a novel therapeutic option in Raynaud\u2019s disease. Arch Intern Med. 2006;166:231\u20133.","journal-title":"Arch Intern Med"},{"key":"6851_CR72","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","volume":"112","author":"R Fries","year":"2005","unstructured":"Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in thetreatment of Raynaud\u2019s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980\u20135.","journal-title":"Circulation"},{"key":"6851_CR73","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/chest.10-0969","volume":"140","author":"LJ Rubin","year":"2011","unstructured":"Rubin LJ, Badesch DB, Flemming TR, et al. Long-term treatmentwith sildenafil citrate in pulmonary arterial hypertension. TheSUPER-2 Study. Chest. 2011;140:1274\u201383.","journal-title":"Chest"},{"key":"6851_CR74","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","volume":"183","author":"ZC Jing","year":"2011","unstructured":"Jing ZC, Shen JY, Wu BX, et al. Vardenafil for the treatment ofpulmonary arterial hypertension. Am J Respir Crit Care Med. 2011;183:1723\u20139.","journal-title":"Am J Respir Crit Care Med"},{"key":"6851_CR75","doi-asserted-by":"crossref","unstructured":"Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy inpulmonary arterial hypertension 2009;119:2894\u2013903.","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"issue":"6","key":"6851_CR76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4111\/kju.2012.53.6.377","volume":"53","author":"HH Sung","year":"2012","unstructured":"Sung HH, Lee SW. Chronic low dosing of phosphodiesterase type 5 inhibitor for erectile dysfunction. Korean J Urol. 2012;53(6):377\u201385.","journal-title":"Korean J Urol"},{"key":"6851_CR77","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4065\/84.2.139","volume":"84","author":"A Nera","year":"2009","unstructured":"Nera A. Erectile dysfunction and cardiovascular disease: efficacyand safety of phosphodiesterase type 5 inhibitors in men with bothcondtions. Mayo Clin Proc. 2009;84:139\u201348.","journal-title":"Mayo Clin Proc"},{"key":"6851_CR78","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.109.147686","volume":"56","author":"JJ Oliver","year":"2010","unstructured":"Oliver JJ, Dear JW, Webb DJ. Clinical potential of combinedorganic nitrate and phosphodiesterase type 5 inhibitor in treatmentresistant hypertension. Hypertension. 2010;56:62\u20137.","journal-title":"Hypertension"},{"key":"6851_CR79","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1161\/01.CIR.0000146906.42375.D3","volume":"110","author":"RA Kloner","year":"2004","unstructured":"Kloner RA. Cardiovascular effects of the 3 phosphodiesterase-5inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110:3149\u201355.","journal-title":"Circulation"},{"issue":"12B","key":"6851_CR80","doi-asserted-by":"publisher","first-page":"42M","DOI":"10.1016\/j.amjcard.2005.07.011","volume":"96","author":"RA Kloner","year":"2005","unstructured":"Kloner RA. Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol. 2005;96(12B):42M\u20136M.","journal-title":"Am J Cardiol"},{"issue":"1","key":"6851_CR81","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/ijir.2009.48","volume":"22","author":"F Dadkhah","year":"2010","unstructured":"Dadkhah F, Safarinejad MR, Asgari MA, et al. Atorvastatin improves the response to sildenafil in hypercholesterolemic men with erectile dysfunction not initially responsive to sildenafil. Int J Impot Res. 2010;22(1):51\u201360.","journal-title":"Int J Impot Res"},{"key":"6851_CR82","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pupt.2017.08.002","volume":"46","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Wu S. Effects of fasudil on pulmonary hypertension in clinical practice. Pulm Pharmacol Ther. 2017;46:54\u201363. \n                    https:\/\/doi.org\/10.1016\/j.pupt.2017.08.002\n                    \n                  .","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"6851_CR83","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1253\/circj.CJ-13-1174","volume":"78","author":"M Elias-Al-Mamun","year":"2014","unstructured":"Elias-Al-Mamun M, Satoh K, Tanaka S, et al. Combination therapy with fasudil and sildenafil ameliorates monocrotaline-induced pulmonary hypertension and survival in rats. Circ J. 2014;78(4):967\u201376.","journal-title":"Circ J"},{"key":"6851_CR84","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.biopha.2016.10.009","volume":"84","author":"AE El-Sisi","year":"2016","unstructured":"El-Sisi AE, Sokar SS, Abu-Risha SE, et al. Combination of tadalafil and diltiazem attenuatesrenal ischemia reperfusion-induced acute renal failure in rats. Biomed Pharmacother. 2016;84:861\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"6851_CR85","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11886-017-0918-y","volume":"19","author":"LL Zullig","year":"2017","unstructured":"Zullig LL, Ramos K3, Bosworth HB. Improving medication adherence in coronary heart disease. Curr Cardiol Rep. 2017;19(11):113.","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"6851_CR86","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1161\/STROKEAHA.117.018140","volume":"48","author":"J Kim","year":"2017","unstructured":"Kim J, Lee HS, Nam CM, et al. Effects of statin intensity and adherence on the long-term prognosis after acute ischemic stroke. Stroke. 2017;48(10):2723\u201330.","journal-title":"Stroke"},{"issue":"1","key":"6851_CR87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12944-017-0544-0","volume":"16","author":"G Xie","year":"2017","unstructured":"Xie G, Sun Y, Myint PK, et al. Six-month adherence to statin use and subsequent risk of major adverse cardiovascular events (MACE) in patients discharged with acute coronary syndromes. Lipids Health Dis. 2017;16(1):155.","journal-title":"Lipids Health Dis"},{"issue":"6","key":"6851_CR88","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/01.mlr.0000163641.86870.af","volume":"43","author":"MC Sokol","year":"2005","unstructured":"Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005 Jun;43(6):521\u201330.","journal-title":"Med Care"},{"key":"6851_CR89","first-page":"47","volume":"1","author":"RC Rosen","year":"1997","unstructured":"Rosen RC. Sexual dysfunction as an obstacle to compliance with antihypertensive therapy. Blood Press Suppl. 1997;1:47\u201351.","journal-title":"Blood Press Suppl"},{"key":"6851_CR90","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","volume":"151","author":"HA Feldman","year":"1994","unstructured":"Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54\u201361.","journal-title":"J Urol"},{"key":"6851_CR91","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0895-7061(00)01214-0","volume":"14","author":"R Fogari","year":"2001","unstructured":"Fogari R, Zoppi A, Poletti L, et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14:27\u201331.","journal-title":"Am J Hypertens"},{"key":"6851_CR92","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/PPA.S3796","volume":"2","author":"CI Voils","year":"2008","unstructured":"Voils CI, Sandelowski M, Dahm P, et al. Selective adherence to antihypertensive medications as a patient-driven means to preserving sexual potency. Patient Prefer Adherence. 2008;2:201\u20136.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"6851_CR93","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/sm2.15","volume":"1","author":"M Kimura","year":"2013","unstructured":"Kimura M, Shimura S, Tai T, et al. A web-based survey of erection hardness score and its relationship to aging, sexual behavior, confidence, and risk factors in Japan. Sex Med. 2013;1(2):76\u201386.","journal-title":"Sex Med"},{"key":"6851_CR94","first-page":"185","volume":"18","author":"H Intili","year":"1998","unstructured":"Intili H, Nier D. Self-esteem and depression in men who present with erectile dysfunction. Urol Nurs. 1998;18:185\u20137.","journal-title":"Urol Nurs"},{"key":"6851_CR95","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0210-4806(05)73280-0","volume":"29","author":"A Martin-Morales","year":"2005","unstructured":"Martin-Morales A, Meijide Rico F, Garcia Gonzalez JI, et al. Psychological impact of erectile dysfunction on self-esteem and self-confidence. Actas Urol Esp. 2005;29:493\u20138.","journal-title":"Actas Urol Esp"},{"key":"6851_CR96","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0090-4295(98)00292-1","volume":"52","author":"R Shabsigh","year":"1998","unstructured":"Shabsigh R, Klein LT, Seidman S, et al. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology. 1998;52:848\u201352.","journal-title":"Urology"},{"issue":"21","key":"6851_CR97","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/eurheartj\/eht462","volume":"35","author":"DL Hare","year":"2014","unstructured":"Hare DL, Toukhsati SR, Johansson P, et al. Depression and cardiovascular disease: a clinical review. Eur Heart J. 2014;35(21):1365\u201372.","journal-title":"Eur Heart J"},{"issue":"671","key":"6851_CR98","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.3399\/bjgp18X696365","volume":"68","author":"A Ju","year":"2018","unstructured":"Ju A, Hanson CS, Banks E, et al. Patient beliefs and attitudes to taking statins: systematic review of qualitative studies. Br J Gen Pract. 2018;68(671):e408\u201319.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"6851_CR99","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1007\/s10943-017-0384-2","volume":"56","author":"AJ Janssen-Niemeijer","year":"2017","unstructured":"Janssen-Niemeijer AJ, Visse M, Van Leeuwen R, et al. The role of spirituality in lifestyle changing among patients with chronic cardiovascular diseases: a literature review of qualitative studies. J Relig Health. 2017;56(4):1460\u201377.","journal-title":"J Relig Health"},{"issue":"7","key":"6851_CR100","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1111\/jsm.12014","volume":"10","author":"CR Mazzola","year":"2013","unstructured":"Mazzola CR, Deveci S, Teloken P, et al. Exploring the association between erectile rigidity and treatment adherence with sildenafil. J Sex Med. 2013;10(7):1861\u20136.","journal-title":"J Sex Med"},{"issue":"8","key":"6851_CR101","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ijcp.12074","volume":"67","author":"WB Smith 2nd","year":"2013","unstructured":"Smith WB 2nd, McCaslin IR, Gokce A, et al. PDE5 inhibitors: considerations for preference and long-term adherence. Int J Clin Pract. 2013;67(8):768\u201380.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"6851_CR102","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000477496","volume":"99","author":"Z Peng","year":"2017","unstructured":"Peng Z, Yang L, Dong Q, et al. Efficacy and safety of tadalafil once-a-day versus tadalafil on-demand in patients with erectile dysfunction: a systematic review and meta-analyses. Urol Int. 2017;99(3):343\u201352.","journal-title":"Urol Int"},{"key":"6851_CR103","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.urology.2017.08.031","volume":"112","author":"UK Bansal","year":"2018","unstructured":"Bansal UK, Jones C, Fuller TW, et al. The efficacy of tadalafil daily vs on demand in the treatment of erectile dysfunction: a systematic review and meta-analysis. Urology. 2018;112:6\u201311.","journal-title":"Urology"},{"issue":"8","key":"6851_CR104","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1037\/amp0000316","volume":"73","author":"HB Bosworth","year":"2018","unstructured":"Bosworth HB, Blalock DV, Hoyle RH, et al. The role of psychological science in efforts to improve cardiovascular medication adherence. Am Psychol. 2018;73(8):968\u201380.","journal-title":"Am Psychol"},{"issue":"7","key":"6851_CR105","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1111\/jsm.12186","volume":"10","author":"P Costa","year":"2013","unstructured":"Costa P, Grandmottet G, Mai HD, et al. Impact of a first treatment with phosphodiesterase inhibitors on men and partners\u2019 quality of sexual life: results of a prospective study in primary care. J Sex Med. 2013;10(7):1850\u201360.","journal-title":"J Sex Med"},{"issue":"10","key":"6851_CR106","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s11255-017-1644-5","volume":"49","author":"B Gong","year":"2017","unstructured":"Gong B, Ma M, Xie W, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017;49(10):1731\u201340.","journal-title":"Int Urol Nephrol"},{"issue":"6","key":"6851_CR107","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/j.1464-410X.2006.06501.x","volume":"98","author":"H Tinel","year":"2006","unstructured":"Tinel H, Stelte-Ludwig B, H\u00fctter J, et al. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int. 2006;98(6):1259\u201363.","journal-title":"BJU Int"},{"issue":"11","key":"6851_CR108","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.2174\/138945011611151013164756","volume":"16","author":"P Brousil","year":"2015","unstructured":"Brousil P, Shabbir M, Zacharakis E, et al. PDE-5 inhibitors for BPH-associated LUTS. Curr Drug Targets. 2015;16(11):1180\u20136.","journal-title":"Curr Drug Targets"},{"issue":"4","key":"6851_CR109","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrurol.2014.53","volume":"11","author":"S Cellek","year":"2014","unstructured":"Cellek S, Cameron NE, Cotter MA, et al. Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. Nat Rev Urol. 2014;11(4):231\u201341.","journal-title":"Nat Rev Urol"},{"issue":"1","key":"6851_CR110","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/ijcp.12044","volume":"67","author":"AD Seftel","year":"2013","unstructured":"Seftel AD, de la Rosette J, Birt J, et al. Coexisting lower urinary tract symptoms and erectile dysfunction: a systematic review of epidemiological data. Int J Clin Pract. 2013;67(1):32\u201345.","journal-title":"Int J Clin Pract"},{"issue":"2","key":"6851_CR111","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ijir.2016.8","volume":"28","author":"IA Korneyev","year":"2016","unstructured":"Korneyev IA, Alexeeva TA, Al-Shukri SH, et al. Prevalence and risk factors for erectile dysfunction and lower urinary tract symptoms in Russian Federation men: analysis from a national population-based multicenter study. Int J Impot Res. 2016;28(2):74\u20139.","journal-title":"Int J Impot Res"},{"key":"6851_CR112","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.12659\/MSM.891180","volume":"20","author":"J Song","year":"2014","unstructured":"Song J, Shao Q, Tian Y, et al. Lower urinary tract symptoms, erectile dysfunction, and their correlation in men aged 50 years and above: a cross-sectional survey in Beijing, China. Med Sci Monit. 2014;20:2806\u201310.","journal-title":"Med Sci Monit"},{"issue":"6","key":"6851_CR113","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40266-014-0177-1","volume":"31","author":"M Gacci","year":"2014","unstructured":"Gacci M, Carini M, Salvi M, et al. Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. Drugs Aging. 2014;31(6):425\u201339.","journal-title":"Drugs Aging"},{"issue":"1","key":"6851_CR114","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrurol.2017.181","volume":"15","author":"FZ M\u00f3nica","year":"2018","unstructured":"M\u00f3nica FZ, Antunes E. Stimulators and activators of soluble guanylate cyclase for urogenital disorders. Nat Rev Urol. 2018;15(1):42\u201354.","journal-title":"Nat Rev Urol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-019-06851-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-019-06851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T19:10:51Z","timestamp":1579806651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-019-06851-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":114,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["6851"],"URL":"https:\/\/doi.org\/10.1007\/s10557-019-06851-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"24 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}}]}}